Spiro George  Rombotis net worth and biography

Spiro Rombotis Biography and Net Worth

Spiro Rombotis. Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has over 36 years at three public biotechs and two pharmas. He participated in in-licensing, clinical development, regulatory approval, partnering and commercial launch of several drugs, mainly in inflammation and hematology/oncology, including Abelcet®, Evacet/Myocet®, ProHance®, Remicade® and Reopro®. Major functional roles included international operations and business development as Vice President at Liposome (subsequently acquired by Elan) and previously Vice President in the pharmaceuticals division of Bristol-Myers Squibb. He began his career in the early ‘80s, after training at Novartis, as one of the first employees of Centocor (subsequently acquired by Johnson & Johnson). He holds an MBA and MPH (Hospital & Health Services Management) with honors, Kellogg School of Management, Northwestern University and a BA, Williams College. He serves on the Board of Trustees of BioNJ, the NJ biotech association. We believe Mr. Rombotis’ qualifications to serve on the Board of Directors include his role as President and Chief Executive Officer of our Company, his extensive knowledge and experience in the biotechnology and life sciences industry and his leadership, strategic guidance and operational vision.

What is Spiro George Rombotis' net worth?

The estimated net worth of Spiro George Rombotis is at least $28,486.20 as of December 21st, 2023. Mr. Rombotis owns 68,658 shares of Cyclacel Pharmaceuticals stock worth more than $28,486 as of January 9th. This net worth estimate does not reflect any other investments that Mr. Rombotis may own. Additionally, Mr. Rombotis receives a salary of $612,470.00 as CEO at Cyclacel Pharmaceuticals. Learn More about Spiro George Rombotis' net worth.

How old is Spiro George Rombotis?

Mr. Rombotis is currently 65 years old. There are 3 older executives and no younger executives at Cyclacel Pharmaceuticals. Learn More on Spiro George Rombotis' age.

What is Spiro George Rombotis' salary?

As the CEO of Cyclacel Pharmaceuticals, Inc., Mr. Rombotis earns $612,470.00 per year. Learn More on Spiro George Rombotis' salary.

How do I contact Spiro George Rombotis?

The corporate mailing address for Mr. Rombotis and other Cyclacel Pharmaceuticals executives is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. Cyclacel Pharmaceuticals can also be reached via phone at (908) 517-7330 and via email at ir@cyclacel.com. Learn More on Spiro George Rombotis' contact information.

Has Spiro George Rombotis been buying or selling shares of Cyclacel Pharmaceuticals?

Spiro George Rombotis has not been actively trading shares of Cyclacel Pharmaceuticals during the last ninety days. Most recently, on Thursday, December 21st, Spiro George Rombotis bought 6,070 shares of Cyclacel Pharmaceuticals stock. The stock was acquired at an average cost of $3.31 per share, with a total value of $20,091.70. Following the completion of the transaction, the chief executive officer now directly owns 68,658 shares of the company's stock, valued at $227,257.98. Learn More on Spiro George Rombotis' trading history.

Who are Cyclacel Pharmaceuticals' active insiders?

Cyclacel Pharmaceuticals' insider roster includes Sam Barker (Director), and Spiro Rombotis (CEO). Learn More on Cyclacel Pharmaceuticals' active insiders.

Spiro George Rombotis Insider Trading History at Cyclacel Pharmaceuticals

See Full Table

Spiro George Rombotis Buying and Selling Activity at Cyclacel Pharmaceuticals

This chart shows Spiro George Rombotis's buying and selling at Cyclacel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20k-$10k$0$10k$20kTotal Insider BuyingTotal Insider Selling

Cyclacel Pharmaceuticals Company Overview

Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Read More

Today's Range

Now: $0.41
Low: $0.35
High: $0.45

50 Day Range

MA: $0.39
Low: $0.32
High: $0.65

2 Week Range

Now: $0.41
Low: $0.31
High: $4.00

Volume

1,677,733 shs

Average Volume

24,054,867 shs

Market Capitalization

$2.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35